Get started
Author

Juan Ignacio Delgado Mingorance

Observed names: J. Ignacio Delgado Mingorance, Juan I. Delgado Mingorance
OpenAlex ID: A5069431908
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 479
PDF
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
2025 · Maria De Santis, Joan Palou Redorta, et al. · The Lancet · 77
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1
2021 · Eva Maria Ciruelos, Hope S. Rugo, et al. · Journal of Clinical Oncology · 38
PDF
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
2023 · Silke Gillessen, Giuseppe Procopio, et al. · Journal of Clinical Oncology · 9
PDF
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
2019 · Luis Manso, Fernando Moreno Antón, et al. · The Breast Journal · 9
PDF
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
2022 · Javier Salvador Bofill, Fernando Moreno Anton, et al. · The Breast · 6
PDF
Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.
2016 · Adam Brufsky, Sung-Bae Kim, et al. · Journal of Clinical Oncology · 6
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
2026 · Padmanee Sharma, Michael Krainer, et al. · Nature Communications · 3
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.
2020 · Jaime Feliu Batlle, Monica Jorge Fernandez, et al. · Journal of Clinical Oncology · 3
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
2019 · Dejan Juric, Sibylle Loibl, et al. · Journal of Clinical Oncology · 1
Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin).
2015 · Luis Manso, Fernando Moreno, et al. · Journal of Clinical Oncology
Works count: 13
Citation count: 3,594
H-index: 7
I10-index: 5
Year
Topic
Type